Creative Planning Acelrx Pharmaceuticals Inc Transaction History

Creative Planning

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 03, 2022	BUY	$0.2 - $0.35 $3,100 - $5,425	15,500 New	15,500 $3,000
Q3 2019 Nov 01, 2019	SELL	$2.1 - $2.87 $89,716 - $122,612	-42,722 Closed	0 $0
Q2 2019 Jul 26, 2019	SELL	$2.1 - $3.93 $168 - $314	-80 Reduced 0.19%	42,722 $108,000
Q1 2019 Apr 24, 2019	SELL	$2.35 - $3.83 $2,350 - $3,830	-1,000 Reduced 2.28%	42,802 $149,000
Q4 2018 Feb 01, 2019	SELL	$2.13 - $4.8 $3,024 - $6,816	-1,420 Reduced 3.14%	43,802 $101,000
Q3 2018 Oct 25, 2018	BUY	$2.6 - $4.6 $84,557 - $149,601	32,522 Added 256.08%	45,222 $174,000
Q2 2018 Jul 20, 2018	SELL	$2.13 - $4.2 $2,130 - $4,200	-1,000 Reduced 7.3%	12,700 $43,000
Q4 2017 Jan 17, 2018	SELL	$1.75 - $5.5 $1,750 - $5,500	-1,000 Reduced 6.8%	13,700 $28,000
Q3 2017 Oct 17, 2017	BUY	$2.9 - $4.6 $42,630 - $67,620	14,700	14,700 $68,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.